BTK and B-cell chronic lymphocytic leukemia: New therapies for Richter transformation (RT) of chronic lymphocytic leukemia (CLL) are necessary, as current treatments are ineffective for relapsed/refractory disease and prognosis remains poor, particularly for those previously treated for CLL.1–3 We report outcomes with the next-generation Bruton tyrosine kinase inhibitor zanubrutinib, alone or in combination with the programmed death-1 inhibitor tislelizumab, from 2 studies.